drugset / Trial / NCT00465725

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

NCT00465725

Phase 1 Completed 18 enrolled Poniard Pharmaceuticals
RandomizedCrossoverOpen-labelTreatment

Summary

Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve after treatment with chemotherapy. In these studies, picoplatin was administered intravenously. A capsule containing picoplatin has been formulated. This study will investigate the activity of the oral capsule in humans. Participants with advanced solid tumors will be enrolled.

Timeline

Start
2007-04
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Picoplatin Small molecule 120 mg/m2 Intravenous
Subject Picoplatin Small molecule 200 mg Intravenous
Subject Picoplatin Small molecule 300 mg Intravenous
Subject Picoplatin Small molecule 400 mg Intravenous